Pacific Edge has secured new US payer access and a Veterans Administration purchasing agreement while proposed Medicare price increases could materially lift revenue per test. The recovery remains unfinished, however, with US commercial volumes down 13% and final Medicare coverage still pending.
- Proposed 2027 Medicare prices of US$1,026 for Monitor and US$1,058 for Triage
- Blue Cross plans in North and South Carolina to provide in-network access to nearly 8 million lives
- First facility-level US Veterans Administration Blanket Purchase Agreement secured
- US commercial volumes fell 13% to 2,867 tests in Q2 27
- Triage Plus rose to 5.6% of US tests, reaching 10.8% in September
Medicare pricing improves, but coverage remains the prize
Pacific Edge Limited (NZX/ASX:PEB) is assembling the commercial pieces of a US recovery, but the central piece is still missing: final Medicare coverage for its Cxbladder tests. Proposed 2027 reimbursement rates would lift Cxbladder Monitor to US$1,026 and Cxbladder Triage to US$1,058, from the current US$760, subject to finalisation by the Centers for Medicare & Medicaid Services.
The proposed rates represent increases of about 35% and 39% respectively. They could improve revenue per test, margins and Pacific Edge's negotiating position with commercial payers, but pricing does not establish coverage. The company continues to expect Novitas to finalise its Local Coverage Determination by the end of calendar 2026, making that decision the clearest near-term test of whether the recovery can move from policy pathway to reimbursed volume. The company previously positioned the draft Medicare coverage pathway as the basis for a Medicare-led recovery.
Blue Cross and VA agreements widen the route to payment
Pacific Edge has also converted favourable policy into an in-network contract with Blue Cross plans in North and South Carolina. From 1 November 2026, Cxbladder Triage will be reimbursed at contracted rates for members of plans covering nearly 8 million people. The company describes this as its first US commercial payer arrangement combining favourable medical policy with in-network status.
A separate facility-level Blanket Purchase Agreement with the Marion, Illinois Veterans Administration allocates about US$1.3 million over five years for Cxbladder Triage Plus and Monitor. The agreement does not appear to be a system-wide VA commitment, but Pacific Edge says it removes an administrative funding obstacle for the facility and provides a route to payment for testing in a predominantly high-risk patient population.
Lower volumes expose the cost of waiting
The operating figures show why the pending Medicare decision matters. US commercial tests fell 13% quarter on quarter to 2,867 in Q2 27, as Pacific Edge reduced commercial spending, concentrated on productive accounts and shifted towards intermediate-risk microhematuria patients. Asia Pacific commercial volumes rose 3.7% to 1,201 tests, while total laboratory throughput increased 2.7% to 5,258, partly because more clinical study samples were processed.
Within the weaker US volume number, the product mix is moving in the direction management wants. Triage Plus accounted for 5.6% of US tests in the quarter, up from 0.8% in Q1 27, and reached 10.8% in September. The test is described as higher margin, but Pacific Edge has not quantified the revenue or earnings effect of the mix shift. Its Kaiser Permanente Southern California concordance study has completed enrolment of about 2,000 patients, with analysis still to come before any transition from Triage to Triage Plus.
Clinical evidence adds weight to the commercial pitch
Two new publications strengthen the evidence base behind the payer strategy. A Canterbury study of 4,512 haematuria referrals found that adding Cxbladder Triage to the pathway reduced the median wait from primary-care referral to specialist assessment by 14.8 days and reduced the wait to first operative treatment for bladder cancer by 15.0 days. Monthly referrals to specialist urology also fell by 6.9, or roughly 83 referrals a year, in the audited period.
The AUSSIE study, accepted for publication in the BJU International, evaluated 691 Australian patients and reported a 74% overall test-negative rate. In the microhaematuria subgroup, the reported negative predictive value was 100%, while the test-negative rate varied by risk category. Those findings are supportive, but they come from a defined study population and do not themselves settle reimbursement or adoption decisions. Pacific Edge is also progressing microDRIVE, pooled analyses and the CREDIBLE study, with several publications expected during 2027.
Bottom Line?
Pacific Edge now has stronger pricing signals and more routes to US payment, but the investment case still turns on whether Novitas finalises coverage and whether reimbursed volume recovers before the current spending discipline becomes a constraint.
Questions in the middle?
- Will Novitas finalise Medicare coverage for Triage and Triage Plus by the company's expected year-end 2026 timetable?
- How quickly will the Blue Cross contracts and Marion VA agreement translate into paid test volumes?
- Can the higher-margin Triage Plus mix offset the decline in total US commercial tests while Pacific Edge waits for broader coverage?